PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 203 filers reported holding PDL BIOPHARMA INC in Q2 2016. The put-call ratio across all filers is 2.73 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $8,000 | -96.5% | 2,758 | -95.9% | 0.00% | -95.2% |
| Q3 2017 | $228,000 | +240.3% | 67,233 | +146.3% | 0.02% | +250.0% |
| Q2 2017 | $67,000 | -72.4% | 27,300 | -74.5% | 0.01% | -73.9% |
| Q1 2017 | $243,000 | +56.8% | 107,100 | +46.3% | 0.02% | +21.1% |
| Q4 2016 | $155,000 | +18.3% | 73,200 | +87.1% | 0.02% | +35.7% |
| Q3 2016 | $131,000 | +39.4% | 39,129 | +31.3% | 0.01% | +7.7% |
| Q2 2016 | $94,000 | -45.7% | 29,800 | -13.5% | 0.01% | -48.0% |
| Q3 2015 | $173,000 | +440.6% | 34,458 | +665.7% | 0.02% | +525.0% |
| Q1 2015 | $32,000 | -8.6% | 4,500 | 0.0% | 0.00% | -20.0% |
| Q4 2014 | $35,000 | -73.9% | 4,500 | -67.4% | 0.01% | -72.2% |
| Q2 2014 | $134,000 | +135.1% | 13,800 | +102.9% | 0.02% | +125.0% |
| Q1 2014 | $57,000 | -27.8% | 6,800 | -27.0% | 0.01% | -38.5% |
| Q4 2013 | $79,000 | +139.4% | 9,320 | +121.9% | 0.01% | +160.0% |
| Q3 2013 | $33,000 | – | 4,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |